Literature DB >> 11513151

The centromeric part of the human natural killer (NK) receptor complex: lectin-like receptor genes expressed in NK, dendritic and endothelial cells.

E Hofer1, Y Sobanov, C Brostjan, H Lehrach, M Düchler.   

Abstract

The human natural killer (NK) receptor complex encompasses a region of about 2 Mb on the short arm of chromosome 12. It contains at least 18 lectin-like receptor genes, of which some are expressed in NK and NK/T cells and function as NK receptors. Close to the CD94 and NKG2 NK receptor genes in the centromeric part, a novel family of genes, expressed in myeloid, dendritic and/or endothelial cells, recently became evident. These genes encode a receptor for oxidized low density lipoprotein in endothelial cells and three other receptors potentially serving regulatory functions in dendritic cells. Although the overall structure of the human NK receptor complex is similar to the syntenic rodent regions, the centromeric part lacks the cluster of Ly49 genes. This supports the notion that recognition of MHC class Ia molecules has evolved separately in rodents and humans in the lectin-like Ly49 and the killer immunoglobulin-like receptors, respectively. In the telomeric part, other lectin-like genes expressed in different hematopoietic lineages are found. The receptors of the NK receptor complex apparently serve important functions in several leukocytes and in endothelial cells, and the exact role of these receptors, their ligands, and their distinct and co-ordinate regulation in different cell lineages warrants further investigation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11513151     DOI: 10.1034/j.1600-065x.2001.1810101.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  10 in total

1.  Complex expression of natural killer receptor genes in single natural killer cells.

Authors:  Zaheed Husain; Chester A Alper; Edmond J Yunis; Devendra P Dubey
Journal:  Immunology       Date:  2002-07       Impact factor: 7.397

2.  The characteristics of NK cells in Schistosoma japonicum-infected mouse spleens.

Authors:  Lu Li; Hefei Cha; Xiuxue Yu; Hongyan Xie; Changyou Wu; Nuo Dong; Jun Huang
Journal:  Parasitol Res       Date:  2015-08-29       Impact factor: 2.289

Review 3.  The CD94/NKG2 family of receptors: from molecules and cells to clinical relevance.

Authors:  Francisco Borrego; Madhan Masilamani; Alina I Marusina; Xiaobin Tang; John E Coligan
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 4.  The C-type lectin-like receptors of Dectin-1 cluster in natural killer gene complex.

Authors:  Jianhui Xie
Journal:  Glycoconj J       Date:  2012-07-12       Impact factor: 2.916

5.  High diversification of CD94 by alternative splicing in New World primates.

Authors:  John A Galindo; Luis F Cadavid
Journal:  Immunogenetics       Date:  2013-01-31       Impact factor: 2.846

6.  Urochordates and the origin of natural killer cells: identification of a CD94/NKR-P1-related receptor in blood cells of Botryllus.

Authors:  Konstantin Khalturin; Matthias Becker; Baruch Rinkevich; Thomas C G Bosch
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-07       Impact factor: 11.205

Review 7.  Evolution of the C-type lectin-like receptor genes of the DECTIN-1 cluster in the NK gene complex.

Authors:  Susanne Sattler; Hormas Ghadially; Erhard Hofer
Journal:  ScientificWorldJournal       Date:  2012-04-01

Review 8.  Inhibitory C-type lectin receptors in myeloid cells.

Authors:  Pierre Redelinghuys; Gordon D Brown
Journal:  Immunol Lett       Date:  2010-10-08       Impact factor: 3.685

9.  The evolution of the natural killer complex; a comparison between mammals using new high-quality genome assemblies and targeted annotation.

Authors:  John C Schwartz; Mark S Gibson; Dorothea Heimeier; Sergey Koren; Adam M Phillippy; Derek M Bickhart; Timothy P L Smith; Juan F Medrano; John A Hammond
Journal:  Immunogenetics       Date:  2017-02-09       Impact factor: 2.846

10.  CAM and NK Cells.

Authors:  Kazuyoshi Takeda; Ko Okumura
Journal:  Evid Based Complement Alternat Med       Date:  2004-06-01       Impact factor: 2.629

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.